Insider Selling: NantHealth (NH) COO Sells 7,005 Shares of Stock

NantHealth (NASDAQ:NH) COO Ronald Allen Louks sold 7,005 shares of the stock in a transaction dated Sunday, May 6th. The shares were sold at an average price of $3.41, for a total transaction of $23,887.05. Following the completion of the sale, the chief operating officer now owns 177,391 shares of the company’s stock, valued at approximately $604,903.31. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ronald Allen Louks also recently made the following trade(s):

Get NantHealth alerts:

On Friday, April 6th, Ronald Allen Louks sold 7,005 shares of NantHealth stock. The shares were sold at an average price of $3.04, for a total transaction of $21,295.20. On Tuesday, March 6th, Ronald Allen Louks sold 7,095 shares of NantHealth stock. The shares were sold at an average price of $3.56, for a total transaction of $25,258.20.

NantHealth stock traded up $0.07 during mid-day trading on Tuesday, reaching $3.48. The company’s stock had a trading volume of 71,400 shares, compared to its average volume of 108,623. NantHealth has a 12-month low of $2.60 and a 12-month high of $5.26. The firm has a market capitalization of $370.30 million, a price-to-earnings ratio of -3.11 and a beta of 0.19. The company has a current ratio of 2.28, a quick ratio of 2.26 and a debt-to-equity ratio of 1.01.

NantHealth (NASDAQ:NH) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.21) earnings per share for the quarter. NantHealth had a negative net margin of 188.81% and a negative return on equity of 54.16%. The business had revenue of $22.30 million during the quarter, compared to analysts’ expectations of $23.50 million. equities research analysts forecast that NantHealth will post -0.61 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in NH. Bank of New York Mellon Corp grew its stake in NantHealth by 40.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 63,149 shares of the company’s stock valued at $260,000 after buying an additional 18,300 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new position in NantHealth in the 3rd quarter valued at approximately $180,000. Dimensional Fund Advisors LP bought a new position in NantHealth in the 3rd quarter valued at $365,000. GSA Capital Partners LLP boosted its holdings in NantHealth by 154.7% in the 3rd quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock valued at $299,000 after purchasing an additional 44,100 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in NantHealth by 157.6% in the 4th quarter. SG Americas Securities LLC now owns 72,521 shares of the company’s stock valued at $221,000 after purchasing an additional 44,372 shares during the period. Institutional investors and hedge funds own 6.27% of the company’s stock.

Several equities research analysts have recently issued reports on NH shares. BidaskClub lowered shares of NantHealth from a “hold” rating to a “sell” rating in a research note on Friday, January 26th. Cowen restated a “buy” rating and set a $4.50 price target on shares of NantHealth in a research note on Tuesday, March 20th. Jefferies Group set a $5.00 price target on shares of NantHealth and gave the stock a “buy” rating in a research note on Wednesday, March 21st. Zacks Investment Research lowered shares of NantHealth from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, ValuEngine upgraded shares of NantHealth from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $4.69.

About NantHealth

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.

Insider Buying and Selling by Quarter for NantHealth (NASDAQ:NH)

Leave a Reply

Your email address will not be published. Required fields are marked *